1.
Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product
by Kelly, Judith P
The Lancet (British edition), 1996, Vol.348 (9039), p.1413-1416

2.
Epidemiological assessment of drug-induced disease
by Kaufman, David W
The Lancet (British edition), 2000, Vol.356 (9238), p.1339-1343

3.
Etomidate versus ketamine for sedation in acutely ill patients
by Kaufman, David
The Lancet (British edition), 2009, Vol.374 (9697), p.1240-1241

4.
Major upper gastrointestinal bleeding and the use of calcium channel blockers
by Kelly, Judith P
The Lancet (British edition), 1999, Vol.353 (9152), p.559-559

5.
Etomidate versus ketamine for sedation in acutely ill patients/Authors' reply
by Nicolas Mongardon
The Lancet (British edition), 2009-10-10, Vol.374 (9697), p.1240

6.
Gastric safety and entericcoated aspirin
by Kelly, Judith Parsells
The Lancet (British edition), 1997, Vol.349 (9049), p.431-431

7.
Association between air pollution and coronary artery calcification within six metropolitan areas in the USA (the Multi-Ethnic Study of Atherosclerosis and Air Pollution): a longit...
by Kaufman, Joel D, Prof
The Lancet (British edition), 2016, Vol.388 (10045), p.696-704

8.
Estimates of global seasonal influenza-associated respiratory mortality: a modelling study
by Iuliano, A Danielle A Danielle
The Lancet (British edition), 2017-12-14, Vol.391 (10127), p.1285-1300

9.
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
by Cohen, Jeffrey A, Prof
The Lancet (British edition), 2012, Vol.380 (9856), p.1819-1828

10.
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled t...
by Reid, David M, Prof
The Lancet (British edition), 2009, Vol.373 (9671), p.1253-1263

11.
Metabolic mediators of body-mass index and cardiovascular risk
by Chiolero, Arnaud
The Lancet (British edition), 2014, Vol.383 (9934), p.2042-2042

12.
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial
by Goodman, Andrew D, Prof
The Lancet (British edition), 2009, Vol.373 (9665), p.732-738

13.
Metabolic mediators of body-mass index and cardiovascular risk
by Wormser, David
The Lancet (British edition), 2014, Vol.383 (9934), p.2042-2043

14.
Patents for intellectual property
by Korn, David
The Lancet (British edition), 2000, Vol.356 (9246), p.2015-2015

15.
BREAST CANCER AND ALCOHOLIC-BEVERAGE CONSUMPTION
by Rosenberg, Lynn
The Lancet (British edition), 1982, Vol.319 (8266), p.267-271

16.
DIAZEPAM AND THE RISK OF BREAST CANCER
by Kaufman, DavidW
The Lancet (British edition), 1982, Vol.319 (8271), p.537-539
